Lyell Immunopharma, Inc.

Healthcare

NASDAQ:LYEL · NASDAQ Global Select

Market Cap $297.28M Beta -0.09 P/E (TTM) -1.1

$12.74 +1.20%

+$0.15 today

52W Low $8.46High $45.00

Vol 0.36M · Avg 0.09M

EPS (TTM) -$11.26Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+41.71%

Period High

$38.60

Period Low

$8.84

Latest

$12.74

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Allogene Therapeutics, Inc.

NASDAQ:ALLO

$488.96M

Cabaletta Bio, Inc.

NASDAQ:CABA

$470.38M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

$349.02M

Amarin Corporation plc

NASDAQ:AMRN

$332.99M

Silence Therapeutics plc

NASDAQ:SLN

$327.57M

Larimar Therapeutics, Inc.

NASDAQ:LRMR

$305.52M

Editas Medicine, Inc.

NASDAQ:EDIT

$256.46M

AC Immune S.A.

NASDAQ:ACIU

$241.71M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

$117.32M

Genelux Corporation

NASDAQ:GNLX

$110.03M

What is the latest LYEL filing?

The latest filing shown is 8-K dated Jun 15, 2026.

How many recent filings does LYEL have?

Intrinsic Alpha currently shows 20 recent filings for LYEL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.